再生元制药公司（Regeneron Pharmaceuticals）宣布，其研发的药物Pasatru已被欧洲药品管理局（EMA）纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。
这一进展标志着Pasatru在通往市场化的道路上迈出了关键一步。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。再生元方面表示，除了欧洲市场外，公司还计划在多个国家和地区同步推进申报工作，以加速该药物的全球可及性。
业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。随着审评的推进，市场将密切关注其后续进展及监管机构的最终决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.